Accurately Identify Multiple Sclerosis (MS) Earlier.

IsolateMS® is a breakthrough RNA blood test that can help neurologists ‘rule in’ or ‘rule out’ a suspected multiple sclerosis (MS) diagnosis at the first sign of symptoms. Working hand-in-hand with clinical observation and other tools currently available, this new test can help neurologists identify MS with greater than 90% accuracy.

Our testing solution is complementary to existing diagnostic strategies (clinical workup, MRI findings, and other laboratory solutions) and delivers a real-time view of disease activity which providers have never had access to before. IsolateMS® presents additional information for the MS specialist to consider as they determine whether or not a patient has clinically definite MS.

Our work tracking Clinically Isolated Syndrome (CIS) patients who later developed multiple sclerosis suggests that unique RNA patterns we detected are present early in the disease process. As outlined in Brain Health: Time Matters in Multiple Sclerosis by G. Giovannoni et al., significant time delays (up to two years) exist between recognition of MS by the general provider and diagnosis by a neurologist. IsolateMS® provides an opportunity to shorten this time frame and identify patients who need the most attention from a specialist.

Providers tell us that ‘ruling out’ a suspected case of MS is just as helpful as ‘ruling in’. Since patients first seek help from their family physicians who may not have experience in diagnosing multiple sclerosis, this test could assist in a referral to a neurologist or MS specialist quickly.

NOTE: At this time, the IsolateMS® test is not available in New York. IQuity will update this list as licenses are obtained.

Download IsolateMS® Provider Brochure

Time Matters

IQIsolate MS logo

“Delayed MS Treatment leads to faster disease progression.”

“Significant delays often occur before a person with symptoms suggestive of MS sees a neurologist for diagnosis and treatment. This is despite diagnosis being 10 times more rapid now than in the 1980s and substantial evidence that early treatment is more effective than later treatment.”

Excerpt from: G. Giovanni, et al.
2015 Brain Health: Health Matters in Multiple Sclerosis
Download the Report

Enroll as an IQuity Provider

Research on IsolateMS

Using samples from diagnosed MS patients as well as healthy subjects, IQuity applied machine learning to develop a proprietary algorithm that accurately identifies multiple sclerosis.

IQuity studied more than 640 subjects, including patients with:

  • multiple sclerosis
  • other neurologic disorders
  • healthy patients
  • unaffected family members of patients with MS

Standard calculations of sensitivity and specificity were employed to determine the accuracy of the results, which are greater than 90%.

Download IsolateMS™ Research Overview

Review our peer-reviewed articles

Increasing the Certainty of an MS Diagnosis is of Value

“Multiple Sclerosis (MS) remains a clinical diagnosis; the certainty of the diagnosis is enhanced by imaging and electrodiagnostic studies. Any test which will increase the certainty of an MS diagnosis is of value to the treating physician. The results are likely to influence both making the diagnosis of MS and implementing therapies that benefit the patients.”

Subramaniam Sriram, MD,
Director, MS Center,
Vanderbilt University Medical Center